Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
The European Journal of Health Economics
Erschienen in: The European Journal of Health Economics 8/2017

01.11.2016 | Original Paper

Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies

verfasst von: Hayley Bennett, Jason Gordon, Beverley Jones, Thomas Ward, Samantha Webster, Anupama Kalsekar, Yong Yuan, Michael Brenner, Phil McEwan

Erschienen in: The European Journal of Health Economics | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatitis C virus (HCV) treatment can reduce the incidence of future infections through removing opportunities for onward transmission. This benefit is not captured in conventional cost-effectiveness evaluations of treatment and is particularly relevant in patient groups with a high risk of transmission, such as those people who inject drugs (PWID), where the treatment rates have been historically low. This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct-acting antiviral (DAA) regimens as a function of treatment uptake rates.

Methods

An established model of HCV disease transmission and progression was used to quantify the impact of treatment uptake (10–100%), within the PWID population, on the cost-effectiveness of a DAA regimen versus pre-DAA standard of care, conducted using daclatasvir plus sofosbuvir in the UK setting as an illustrative example.

Results

The consequences of reduced disease transmission due to treatment were associated with additional net monetary benefit of £24,304–£90,559 per patient treated at £20,000/QALY, when 10–100% of eligible patients receive treatment with 100% efficacy. Dependent on patient genotype, the cost-effectiveness of HCV treatment using daclatasvir plus sofosbuvir improved by 36–79% versus conventional analysis, at 10–100% treatment uptake in the PWID population.

Conclusions

The estimated cost-effectiveness of HCV treatment was shown to improve as more patients are treated, suggesting that the value of DAA regimens to the NHS could be enhanced by improved treatment uptake rates among PWID. However, the challenge for the future will lie in achieving increased rates of treatment uptake, particularly in the PWID population.
Literatur
1.
Shepard, C.W., Finelli, L., Alter, M.J.: Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558–567 (2005)CrossRefPubMed
2.
Hatzakis, A., Chulanov, V., Gadano, A.C., et al.: The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm—volume 2. J. Viral Hepat. 22(Suppl 1), 26–45 (2015)CrossRefPubMed
3.
4.
5.
Afdhal, N.H.: Hepatitis C viral infection in difficult-to-treat populations: an overview. Clin. Liver Dis. 1(3), 63–64 (2012)CrossRef
6.
7.
European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 60(2), 392–420 (2014)CrossRef
8.
Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al.: Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370(3), 211–221 (2014)CrossRefPubMed
9.
Lawitz, E., Mangia, A., Wyles, D., et al.: Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368(20), 1878–1887 (2013)CrossRefPubMed
10.
11.
12.
13.
Hagan, L.M., Sulkowski, M.S., Schinazi, R.F.: Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 60(1), 37–45 (2014)CrossRefPubMedPubMedCentral
14.
Petta, S., Cabibbo, G., Enea, M., et al.: Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 59(5), 1692–1705 (2014)CrossRefPubMed
15.
Gordon, S.C., Pockros, P.J., Terrault, N.A., et al.: Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 56(5), 1651–1660 (2012)CrossRefPubMed
16.
Westbrook, R.H., Dusheiko, G.: Natural history of hepatitis C. J. Hepatol. 61(1), S58–S68 (2014)CrossRefPubMed
17.
National Institute for Health and Care Excellence: NICE technology appraisal guidance [TA331]. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C. https://​www.​nice.​org.​uk/​guidance/​ta331 (2015). Accessed 16 Mar 2016
18.
19.
20.
21.
22.
23.
24.
25.
Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M.: Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J. Hepatol. 54(6), 1137–1144 (2011)CrossRefPubMed
26.
Harris, R.J., Thomas, B., Griffiths, J., et al.: Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J. Hepatol. 61(3), 530–537 (2014)CrossRefPubMed
27.
Martin, N.K., Foster, G.R., Vilar, J., et al.: HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J. Viral Hepat. 22(4), 399–408 (2015)CrossRefPubMed
28.
Cousien, A., Tran, V.C., Deuffic-Burban, S., Jauffret-Roustide, M., Dhersin, J.S., Yazdanpanah, Y.: Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. J. Viral Hepat. 22(3), 213–229 (2015)CrossRefPubMed
29.
Martin, N.K., Vickerman, P., Grebely, J., et al.: Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58(5), 1598–1609 (2013)CrossRefPubMedPubMedCentral
30.
Hellard, M.E., Jenkinson, R., Higgs, P., et al.: Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med. J. Aust. 196(10), 638–641 (2012)CrossRefPubMed
31.
Duberg, A.S., Blach, S., Falconer, K., Kaberg, M., Razavi, H., Aleman, S.: The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand. J. Gastroenterol. 50(2), 233–244 (2015)CrossRefPubMed
32.
Martin, N.K., Vickerman, P., Dore, G.J., et al.: Prioiritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J. Hepatol. 65(1), 17–25 (2016)
33.
Bennett, H., McEwan, P., Sugrue, D., Kalsekar, A., Yuan, Y.: Assessing the long-term impact of treating hepatitis C virus (HCV)-Infected people who inject drugs in the UK and the relationship between treatment uptake and efficacy on future infections. PLoS One 10(5), e0125846 (2015)CrossRefPubMedPubMedCentral
34.
McEwan, P., Kim, R., Yuan, Y.: Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl. Health Econ. Health Policy 11(1), 53–63 (2013)CrossRefPubMed
35.
McEwan, P., Ward, T., Chen, C.-J., et al.: Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Reg. Issues 3, 5–11 (2014)CrossRef
36.
McEwan, P., Ward, T., Yuan, Y., Kim, R., L’Italien, G.: The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 58(1), 54–64 (2013)CrossRefPubMed
37.
McEwan, P., Ward, T., Bennett, H., et al.: Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 10(1), e0117334 (2015)CrossRefPubMedPubMedCentral
38.
Thein, H.H., Yi, Q., Dore, G.J., Krahn, M.D.: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48(2), 418–431 (2008)CrossRefPubMed
39.
Kanwal, F., Kramer, J.R., Ilyas, J., Duan, Z., El-Serag, H.B.: HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV. Hepatology 60(1), 98–105 (2014)CrossRefPubMedPubMedCentral
40.
Townsend, R., McEwan, P., Kim, R., Yuan, Y.: Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 14(8), 1068–1077 (2011)CrossRefPubMed
41.
Shepherd, J., Jones, J., Hartwell, D., Davidson, P., Price, A., Waugh, N.: Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess. 11(11), 1–205 (2007)CrossRefPubMed
42.
Pearlman, B.L., Traub, N.: Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin. Infect. Dis. 52(7), 889–900 (2011)CrossRefPubMed
43.
Akhtar, E., Manne, V., Saab, S.: Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver. Int. 35(1), 30–36 (2014)
44.
Im, G.Y., Dieterich, D.T.: Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterol. Hepatol. (N. Y.) 8(11), 727–765 (2012)
45.
46.
47.
48.
49.
Leidner, A.J., Chesson, H.W., Xu, F., Ward, J.W., Spradling, P.R., Holmberg, S.D.: Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 61(6), 1860–1869 (2015)CrossRefPubMed
50.
Leleu, H., Blachier, M., Rosa, I.: Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J. Viral Hepat. 22(4), 376–383 (2015)CrossRefPubMed
51.
52.
Arain, A., Robaeys, G.: Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J. Gastroenterol. 20(36), 12722–12733 (2014)CrossRefPubMedPubMedCentral
53.
Innes, H., Goldberg, D., Dillon, J., Hutchinson, S.J.: Strategies for the treatment of hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? Gut. 64(11), 1800–1809 (2014)
54.
Hope, V.D., Hickman, M., Ngui, S.L., et al.: Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat. 18(4), 262–270 (2011)CrossRefPubMed
55.
Sweeting, M.J., Hope, V.D., Hickman, M., et al.: Hepatitis C infection among injecting drug users in England and Wales (1992–2006): there and back again? Am. J. Epidemiol. 170(3), 352–360 (2009)CrossRefPubMedPubMedCentral
56.
Kimber, J., Copeland, L., Hickman, M., et al.: Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 341, c3172 (2010)CrossRefPubMedPubMedCentral
57.
Hickman, M., Hope, V., Coleman, B., et al.: Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J. Public Health (Oxf.) 31(3), 374–382 (2009)CrossRef
58.
Cornish, R., Macleod, J., Strang, J., Vickerman, P., Hickman, M.: Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 341, c5475 (2010)CrossRefPubMedPubMedCentral
59.
60.
Allen, E.J., Palmateer, N.E., Hutchinson, S.J., Cameron, S., Goldberg, D.J., Taylor, A.: Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int. J. Drug Policy 23(5), 346–352 (2012)CrossRefPubMed
61.
62.
Vickerman, P., Martin, N., Turner, K., Hickman, M.: Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 107(11), 1984–1995 (2012)CrossRefPubMed
63.
Kemp, P.A., Neale, J., Robertson, M.: Homelessness among problem drug users: prevalence, risk factors and trigger events. Health Soc. Care Community 14(4), 319–328 (2006)CrossRefPubMed
64.
Innes, H.A., Hutchinson, S.J., Allen, S., et al.: Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur. J. Gastroenterol. Hepatol. 24(6), 646–655 (2012)CrossRefPubMed
65.
Micallef, J.M., Kaldor, J.M., Dore, G.J.: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 13(1), 34–41 (2006)CrossRefPubMed
66.
Mondelli, M.U., Cerino, A., Cividini, A.: Acute hepatitis C: diagnosis and management. J. Hepatol. 42(1), S108–S114 (2005)CrossRefPubMed
67.
Turner, K.M.E., Hutchinson, S., Vickerman, P., et al.: The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106(11), 1978–1988 (2011)CrossRefPubMed
68.
Aspinall, E.J., Corson, S., Doyle, J.S., et al.: Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin. Infect. Dis. 57(suppl 2), S80–S89 (2013)CrossRefPubMed
69.
Jacobson, I.M., McHutchison, J.G., Dusheiko, G., et al.: Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405–2416 (2011)CrossRefPubMed
70.
Poordad, F., McCone Jr., J., Bacon, B.R., et al.: Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195–1206 (2011)CrossRefPubMedPubMedCentral
71.
72.
Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health. Technol. Assess. 10(21), 1–113, iii (2006)
73.
Grieve, R., Roberts, J., Wright, M., et al.: Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 55(9), 1332–1338 (2006)CrossRefPubMedPubMedCentral
74.
Martin, N.K., Vickerman, P., Miners, A., et al.: Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55(1), 49–57 (2012)CrossRefPubMed
75.
National Institute for Health and Care Excellence: Technology appraisal 252. Telaprevir for the treatment of genotype 1 chronic hepatitis C. Updated June 2014. http://​www.​nice.​org.​uk/​ta252 (2012). Accessed Feb 2015
76.
77.
78.
Bristol-Myers Squibb Pharmaceuticals Ltd: Final clinical study report AI444040 [data on file]. (2013)
79.
Hadziyannis, S.J., Sette Jr., H., Morgan, T.R., et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346–355 (2004)CrossRefPubMed
80.
Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al.: All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61(4), 1127–1135 (2015)CrossRefPubMedPubMedCentral
Metadaten
Titel
Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies
verfasst von
Hayley Bennett
Jason Gordon
Beverley Jones
Thomas Ward
Samantha Webster
Anupama Kalsekar
Yong Yuan
Michael Brenner
Phil McEwan
Publikationsdatum
01.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 8/2017
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-016-0844-8

Weitere Artikel der Ausgabe 8/2017

The European Journal of Health Economics 8/2017 Zur Ausgabe

Original Paper

Switching gains and health plan price elasticities: 20 years of managed competition reforms in The Netherlands

Original Paper

The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies

Editorial

Market approval for drugs in the EU: time to change direction?

Original Paper

Cost effects of preterm birth: a comparison of health care costs associated with early preterm, late preterm, and full-term birth in the first 3 years after birth

Original Paper

Costs of dementia in the Czech Republic

Original Paper

The impact of minimum wages on population health: evidence from 24 OECD countries